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Dyspnea and Risk in Suspected Coronary Disease
 
Thomas H. Marwick, M.B., B.S., Ph.D.
 
Stress testing for the detection of coronary artery
disease is most useful in patients considered on
clinical grounds to be at intermediate risk.
 
1
 
 The
patient’s age and sex and the nature of chest pain
can be used to provide a simple estimate of the prob-
ability of coronary artery disease.
 
2
 
 Because the ab-
sence of chest pain has traditionally been interpret-
ed to indicate a low likelihood of coronary disease
— and, indeed, a low long-term risk — functional
testing has been thought to contribute little to the
evaluation of patients without angina.
 
3
 
Basing a selection strategy for stress testing on
the evaluation of chest pain has several drawbacks.
First, such strategies have usually been developed
to guide the diagnostic evaluation of patients with
clinically significant coronary artery disease, but
many patients undergo stress testing for other rea-
sons.
 
1
 
 Second, the absence of chest pain is not a
good marker of the absence of coronary artery dis-
ease. Indeed, most patients who die suddenly with-
out known symptoms of chest pain have underly-
ing coronary disease.
 
4
 
 Some subgroups at particular
risk for coronary artery disease (e.g., patients with
diabetes mellitus) have silent ischemia, the outcome
of which appears to be no different from that of
painful ischemia.
 
5
 
 Third, symptoms other than typ-
ical angina may also be important. Although the
presence of atypical chest pain indicates a low prob-
ability of coronary artery disease, possible angina
is nonetheless associated with an increased risk of
death from coronary disease.
 
6 
 
Moreover, even in the
absence of chest pain, the presence of symptoms
such as dyspnea may serve as an angina equivalent
or a marker of underlying cardiac disease.
In this issue of the 
 
Journal
 
, Abidov and cowork-
ers provide evidence that dyspnea is a significant
predictor of the risk of both death from cardiac caus-
es and death from any cause.
 
7
 
 These authors exam-
ined the incremental value of presenting symptoms
in nearly 18,000 patients who underwent myocar-
dial perfusion imaging at rest and during stress.
After a mean follow-up of 2.7 years, patients with
dyspnea at presentation had four times the risk of
death from cardiac causes as did patients with no
symptoms and a significantly increased risk of
death from any cause. The independent predictive
role of dyspnea remained significant after propen-
sity matching.
These findings supplement a reported link be-
tween dyspnea and coronary artery disease,
 
8
 
 as well
as complement the results of two earlier studies
that investigated a prognostic role for dyspnea in
patients undergoing stress testing. In an evalua-
tion of over 3000 patients undergoing stress echo-
cardiography at the Mayo Clinic, Bergeron and
colleagues
 
9
 
 found that patients with a history of
dyspnea were older and had a lower exercise capac-
ity, a lower ejection fraction, and more evidence of
a previous myocardial infarction than those with a
history of chest pain. Ischemia was present in 42
percent of those presenting with dyspnea, as com-
pared with only 19 percent of those presenting with
chest pain. During three years of follow-up, death
from cardiac causes and nonfatal infarction were
most common among patients with dyspnea (5.2
percent and 4.7 percent, respectively). These authors
concluded that patients with unexplained dyspnea
had a high likelihood of ischemia and an increased
incidence of cardiac events. 
In nearly 11,000 patients undergoing stress test-
ing at the Cleveland Clinic,
 
10
 
 dyspnea was the pre-
senting symptom in 8 percent, and the outcome
among patients with dyspnea was similar to that
among patients with typical angina. However, in
a multivariate analysis after propensity matching,
dyspnea was not a significant predictor of an ad-
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verse outcome. As noted by Abidov et al., method-
ologic differences between their study and that of
the Cleveland Clinic may explain the disparate find-
ings.
 
7 
 
Of particular importance may be the inclu-
sion of data from myocardial-perfusion scanning
in the present study but not in that by the Cleve-
land Clinic group.
Dyspnea, defined as difficult, labored, or un-
comfortable breathing, is a nonspecific symptom
provoked by the stimulation of lung and respira-
tory muscle mechanoreceptors, chemoreceptors,
or vascular receptors.
 
11
 
 Many underlying disorders,
including ischemia, deconditioning, heart failure,
obesity, and lung disease, can cause these path-
ways to be activated during exercise.
In the study by Abidov et al., ischemia did appear
to contribute to the adverse effect of dyspnea on
prognosis. Although the percentage of ischemic
myocardium in patients with dyspnea was similar
to that in asymptomatic patients and significantly
less than that in patients with typical angina, the
percentage of patients with dyspnea who had at
least some ischemia was significantly higher than
that among asymptomatic patients and, at least in
patients with known coronary artery disease, sim-
ilar to that among patients with angina. Further-
more, although the difference between the annu-
alized event rates of positive and negative perfusion
scans has been shown to be greater among patients
without dyspnea than among those with dyspnea,
further analysis of the data of Abidov et al. indi-
cates that perfusion imaging can be used to predict
the outcome even in patients presenting with dys-
pnea alone (Fig. 1). Thus, it seems likely that ische-
mia was one of the factors contributing to the in-
fluence of dyspnea on the outcome.
However, because of the limited extent of is-
chemia in many of the patients with dyspnea, and
given the adverse effect of dyspnea even in the ab-
sence of ischemia, the association of dyspnea with
an adverse outcome is unlikely to be attributable
simply to ischemia. Other contributing factors in-
clude exercise capacity, which is recognized as a
major predictor of an adverse outcome
 
12
 
 and which
is often manifested as dyspnea. However, in the
present study, the effect of dyspnea was apparent
in patients subjected to either exercise-induced or
pharmacologically induced stress, implying that
the effect was present irrespective of the patients’
ability to exercise. Heart failure is a likely cause of
dyspnea, and the likelihood that this diagnosis
contributed to an adverse outcome in the study by
Abidov et al.
 
7
 
 is supported by the greater frequen-
cy of advanced age, atrial fibrillation, and left ven-
tricular hypertrophy and enlargement among pa-
tients with dyspnea. Although the effect of dyspnea
on the outcome was apparent in both subgroups
with and those without left ventricular hypertro-
phy and enlargement, diastolic dysfunction (which
was not directly assessed by Abidov et al.) is known
to decrease survival, even in the absence of heart
failure.
 
13
 
Obesity is an increasingly common noncardiac
cause of exercise intolerance. Although Abidov et
al. did not provide data on obesity,
 
7
 
 patients with
dyspnea had a higher prevalence of factors asso-
ciated with obesity (such as diabetes and hyper-
tension). Despite this association, it should be ac-
knowledged that the same adverse effect of dyspnea
was seen in those with and those without factors
associated with obesity. Lung disease is the final
major noncardiac cause of dyspnea. Although not
quantified in the article, the role of lung disease is
evidenced by the predictive role of lung-function
variables.
 
6
 
Dyspnea is a predictor of an adverse outcome in
patients with known or suspected coronary artery
disease who are undergoing stress testing.
 
7,9
 
 Al-
though questions remain about the mechanism,
ischemia, left ventricular dysfunction, and obesity
appear to be plausible contributors. At the very
least, these results should remind us that cardiac
 
Figure 1. Rate of Death from Cardiac Causes among 1091 
Patients with Dyspnea, According to the Severity of the 
Defect on Myocardial-Perfusion Scanning. 
 
P=0.01 for the comparison across the groups.
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symptoms other than chest pain are of value in
identifying patients with suspected coronary artery
disease who should undergo functional testing.
 
From the University of Queensland, Brisbane, Australia.
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Selective Adhesion-Molecule Therapy and Inflammatory 
Bowel Disease — A Tale of Janus?
 
Daniel K. Podolsky, M.D.
 
Although our understanding of the pathogenesis
of the chief forms of inflammatory bowel disease,
Crohn’s disease, and ulcerative colitis remains in-
complete, progress is being made in identifying es-
sential components.
 
1
 
 The presence of large num-
bers of varied leukocytes within affected tissue
where they are normally sparse makes it axiomat-
ic that active disease is dependent on the recruit-
ment of these cell populations. Recruitment is now
known to proceed through a stereotypical series of
steps that depend on selective adhesion molecules
(SAMs). These include cell-surface integrins, het-
erodimers formed by various combinations of 
 
a
 
and 
 
b
 
 subunits. Integrins with an 
 
a
 
4
 
 chain appear
to play an especially important role in the intestine.
 
2
 
a
 
4
 
b
 
1
 
 Integrin (a combination also known as very
late antigen 4 [VLA-4]) is present on most leuko-
cytes but not neutrophils and effects binding to
vascular-cell adhesion molecule 1 on endotheli-
um and dendritic cells. 
 
a
 
4
 
b
 
1
 
 Integrin can also me-
diate binding to components of the extracellular
matrix. In contrast, 
 
a
 
4
 
b
 
7
 
 integrin is expressed on
subpopulations of lymphocytes, natural killer cells,
and monocytes and selectively targets them to so-
called gut-associated lymphoid tissue. Thus, in the
latter guise, 
 
a
 
4
 
 integrin mediates tissue-specific
transport of cells to the intestine.
Circumstantial and direct experimental evi-
dence has suggested that 
 
a
 
4
 
 integrins are impor-
tant in the recruitment and activation of cells in
inflammatory bowel disease. Tissues affected by
inflammatory bowel disease have increased levels
of 
 
a
 
4
 
 integrins and their ligands.
 
3
 
 Moreover, a dis-
ease remarkably similar to ulcerative colitis spon-
taneously develops in cotton-top tamarins, and ad-
ministration of a monoclonal antibody against 
 
a
 
4
 
integrin led to the resolution of colitis in these ani-
mals.
 
4 
 
A subsequent study also showed that treat-
ment with an antibody specific for 
 
a
 
4
 
b
 
7
 
 integrin
was beneficial in the cotton-top tamarin model.
 
5
 
Over the past several years, insights into the
mechanisms of recruitment have prompted efforts
to develop agents to address unmet medical needs
of patients with inflammatory bowel disease. A
number of these agents are currently being evaluat-
ed, but the study that is farthest along is that of na-
talizumab, a humanized IgG4-class monoclonal
antibody directed against 
 
a
 
4
 
 integrins that has al-
ready been approved for the treatment of patients
with multiple sclerosis. Two early studies suggested
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